MeiraGTx Holdings plc
MGTX Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017βFY2025
Last close Β· Oct 23, 2026
$9.21
5.7%What MeiraGTx Holdings plc does
No business description yet.
- Legal name
- MeiraGTx Holdings plc
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 30, 2026
- Accession Β· CIK
- 0001104659-26-036494
0001735438
Revenue and margins
MeiraGTx Holdings plc had $81.4M of revenue in fiscal 2025, up 144.6% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$50.2M in fiscal 2025, β61.7% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
MeiraGTx Holdings plc returned β to shareholders in fiscal 2025. The diluted share count rose 15.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably MeiraGTx Holdings plc can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $138M | $116M | $130M | $104M | $65.9M |
| Interest coverage | β252.6x | β23.5x | β10.3x | β12.4x | β8.7x |
| Current ratio | 2.7x | 1.9x | 2.4x | 2.0x | 0.7x |
| Quick ratio | 2.7x | 1.9x | 2.4x | 2.0x | 0.7x |
| Total assets | $320M | $318M | $327M | $270M | $244M |
| Total liabilities | $135M | $200M | $189M | $202M | $250M |
| Shareholders' equity | $185M | $118M | $138M | $67.8M | β$5.8M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | 2 / 7 | 2 / 7 | 1 / 7 | 2 / 7 | 2 / 7 | 3 / 7 |
| Accruals ratio | β50.2% | β39.1% | β35.5% | 1.7% | β20.2% | β17.7% | 6.6% | β14.5% | β26.4% |
| Altman Z'' | β21.28 | β1.03 | 2.70 | 2.45 | β1.19 | β5.17 | β5.72 | β10.70 | β14.65 |
9 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | β | β | $13.3M | $15.6M | $37.7M | $15.9M | $14.0M | $33.3M | $81.4M |
| Research and development | $22.4M | $33.6M | $24.9M | $33.9M | $66.7M | $85.7M | $104M | $119M | $130M |
| Operating income | β$31.7M | β$78.1M | β$58.3M | β$62.6M | β$72.8M | β$116M | β$137M | β$164M | β$106M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.1M | $0.3M | $4.9M | $13.2M | $13.3M | $12.2M |
| Pretax income | β$31.0M | β$83.3M | β$54.7M | β$58.0M | β$79.6M | β$130M | β$84.0M | β$148M | β$114M |
| Income tax | $0.0M | β$0.5M | $0.0M | $0.0M | $0.0M | β | $0.0M | $0.0M | $0.0M |
| Net income | β$31.0M | β$82.9M | β$54.7M | β$58.0M | β$79.6M | β$130M | β$84.0M | β$148M | β$114M |
| Net income to common | β$31.9M | β$84.7M | β$54.7M | β$58.0M | β$79.6M | β$130M | β$84.0M | β$148M | β$114M |
| Diluted EPS | β$3.72 | β$4.47 | β$1.65 | β$1.54 | β$1.80 | β$2.87 | β$1.49 | β$2.12 | β$1.42 |
| Diluted shares | 0.01B | 0.02B | 0.03B | 0.04B | 0.04B | 0.05B | 0.06B | 0.07B | 0.08B |
| Cash flow | |||||||||
| Cash from operations | β$18.1M | β$58.9M | $20.0M | β$64.0M | β$10.5M | β$73.1M | β$105M | β$104M | β$46.4M |
| Capital expenditure | $10.5M | $11.3M | $9.0M | $20.9M | $46.4M | $45.0M | $20.2M | $5.0M | $3.8M |
| Free cash flow | β$28.6M | β$70.1M | $11.1M | β$84.9M | β$56.9M | β$118M | β$126M | β$109M | β$50.2M |
| Depreciation and amortization | $0.7M | $2.1M | $2.2M | $4.2M | $7.9M | $8.7M | $13.7M | $12.8M | $12.5M |
| Stock-based compensation | $3.0M | $17.9M | $15.9M | $18.4M | $20.8M | $28.6M | $27.7M | $25.2M | $22.1M |
| Balance sheet | |||||||||
| Cash and short-term investments | $8.5M | $68.1M | $227M | $210M | $138M | $116M | $130M | $104M | $65.9M |
| Finance lease liabilities | β | β | $0.1M | $0.0M | $0.0M | β | β | β | $0.1M |
| Current assets | $11.5M | $74.7M | $269M | $273M | $183M | $154M | $160M | $124M | $91.8M |
| Current liabilities | $21.4M | $15.5M | $49.2M | $54.1M | $68.1M | $82.1M | $67.1M | $60.8M | $123M |
| Inventory | β | β | β | β | β | β | β | $0.4M | β |
| Property and equipment, net | $14.3M | $22.0M | $23.9M | $44.0M | $75.9M | $109M | $116M | $103M | $105M |
| Intangible assets | β | β | $0.0M | $2.1M | $1.8M | $1.3M | $1.1M | $0.8M | $0.6M |
| Total assets | $25.9M | $96.9M | $324M | $364M | $320M | $318M | $327M | $270M | $244M |
| Total liabilities | $21.9M | $15.8M | $133M | $125M | $135M | $200M | $189M | $202M | $250M |
| Shareholders' equity | β$47.4M | $81.1M | $191M | $239M | $185M | $118M | $138M | $67.8M | β$5.8M |
| Margins | |||||||||
| Operating margin | β | β | β438.4% | β401.9% | β193.0% | β730.9% | β977.8% | β493.4% | β130.2% |
| EBITDA margin | β | β | β421.5% | β375.1% | β172.1% | β676.1% | β879.9% | β454.9% | β114.8% |
| Net margin | β | β | β411.9% | β372.6% | β211.0% | β814.2% | β599.5% | β444.1% | β140.3% |
| FCF margin | β | β | 83.2% | β545.5% | β150.9% | β741.6% | β895.6% | β328.9% | β61.7% |
| Returns | |||||||||
| Return on capital employed | β711.6% | β96.0% | β21.2% | β20.2% | β28.9% | β49.3% | β52.8% | β78.6% | β86.9% |
| Return on equity | β | β491.9% | β40.3% | β27.0% | β37.5% | β85.5% | β65.7% | β143.5% | β368.2% |
| Return on assets | β120.1% | β135.0% | β26.0% | β16.9% | β23.3% | β40.6% | β26.1% | β49.6% | β44.4% |
| Return on tangible equity | β | β104.5% | β28.7% | β24.5% | β43.3% | β111.4% | β61.3% | β220.6% | β |
| Growth | |||||||||
| Revenue growth | β | β | β | 17.1% | 142.2% | β57.8% | β12.0% | 137.4% | 144.6% |
| FCF growth | β | β | β | β867.2% | β | β | β | β | β |
| Share count change | β | 121.0% | 75.0% | 13.8% | 17.0% | 2.4% | 25.0% | 23.6% | 15.2% |
| Financial health | |||||||||
| Interest coverage | β738.6x | β2,338.4x | β1,198.9x | β450.0x | β252.6x | β23.5x | β10.3x | β12.4x | β8.7x |
| Current ratio | 0.5x | 4.8x | 5.5x | 5.0x | 2.7x | 1.9x | 2.4x | 2.0x | 0.7x |
| Quick ratio | 0.5x | 4.8x | 5.5x | 5.0x | 2.7x | 1.9x | 2.4x | 2.0x | 0.7x |
| Capital allocation | |||||||||
| Capex / revenue | β | β | 67.6% | 134.4% | 122.9% | 282.4% | 143.9% | 14.9% | 4.7% |
| Stock comp / revenue | β | β | 119.8% | 118.3% | 55.1% | 179.8% | 197.7% | 75.7% | 27.2% |
| Quality scores | |||||||||
| Piotroski F-score | β | β | β | 2.0 | 2.0 | 1.0 | 2.0 | 2.0 | 3.0 |
| Altman Z'' | β21.3 | β1.0 | 2.7 | 2.4 | β1.2 | β5.2 | β5.7 | β10.7 | β14.7 |
| Accruals ratio | β50.2% | β39.1% | β35.5% | 1.7% | β20.2% | β17.7% | 6.6% | β14.5% | β26.4% |
Source: SEC EDGAR XBRL filings (CIK 0001735438). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.